The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews

Nikolaos Pyrgidis1,2*, Ioannis Mykoniatis1,2, Anna-Bettina Haidich3, Maria Tirta1, Persefoni Talimtzi1, Dimitrios Kalyvianakis1,2, Andreas Ouranidis4,5 and Dimitrios Hatzichristou1,2

1Institute for the Study of Urological Diseases, Thessaloniki, Greece, 2Urology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Department of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 4Department of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki, Greece, 5Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece

Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes. However, physicians and policymakers require a holistic approach of this topic.

Objective: To summarize the current evidence regarding the efficacy and safety of PDE5 inhibitors for the management of ED through an overview of systematic reviews.

Methods: Studies were identified by searching PubMed, Web of Science, Cochrane Library and Scopus databases, as well as sources of grey literature until June 12, 2021 (PROSPERO: CRD42020216754). We considered systematic reviews, meta-analyses or network meta-analyses of randomized trials that provided outcomes about the efficacy and safety of any approved PDE5 inhibitor (avananfil, sildenafil, tadalafl and vardenafil). We constructed forest plots for meta-analytic effects regarding the change in erectile function, adverse events and dropouts after administration of PDE5 inhibitors in the general population and in specific patient groups.

Results: We included 23 studies with 154,796 participants and a total of 258 meta-analytic effects. Sildenafl 25 mg [Weighted Mean Difference (WMD): 13.08, 95% Confidence Interval (CI): 10.1-16.06] seemed to be statistically superior to all interventions in improving erectile function compared to placebo, but studies with low-dose sildenafl are lacking. Moreover, comparing among different PDE5 inhibitors, sildenafl 50 mg or sildenafl 100 mg were considered the most effective compounds in the general population. The latter derived, however, predominantly from indirect comparisons among different PDE5 inhibitors. Still, sildenafl 100 mg was associated with more treatment-related adverse events and dropouts. Interestingly, low-dose daily tadalafl may be more effective than high-dose on-demand tadalafl (WMD: 1.24, 95% CI: 0.03-2.44). Furthermore, testosterone and PDE5 inhibitors in patients with ED and hypogonadism seem to further improve symptoms, while the addition of a-blockers in patients with urinary symptoms treated...
Introduction

Phosphodiesterase type 5 (PDE5) inhibitors are considered the first-line treatment in patients with erectile dysfunction (ED) due to their safety and efficacy profile (Salonia et al., 2021). To date, seven PDE5 inhibitors exist (avanafil, lodenafl, mirodenafil, sildenafil, tadalafl, udenafil, and vardenafil) and four of them (avanafil, sildenafil, tadalafl, and vardenafil) are currently approved by the EMA and FDA for the management of ED (Goldstein et al., 2019). Established evidence indicates that PDE5 inhibitors are also effective and safe across multiple subgroups of patients with difficult-to-treat ED (Burnett et al., 2018). Similarly, PDE5 inhibitors seem to display beneficial outcomes when they are combined with other effective treatment modalities (Dhir et al., 2011).

Due to the increasing interest in PDE5 inhibitors, available systematic reviews and meta-analyses have explored the effect of PDE5 inhibitors on multiple outcomes (Greenberg et al., 2019). Hence, each systematic review and meta-analysis addresses a specific outcome. On the contrary, physicians and policymakers require, in most cases, a holistic approach of a given topic to facilitate their evidence-based clinical decision-making (Allen and Walter, 2019). In this scope, overviews of systematic reviews and meta-analyses or umbrella reviews are a promising, new approach that assimilates the vast amount of available research and contextualizes the magnitude of a specific topic (Hunt et al., 2018). These studies are growing in popularity, as they provide high level of recommendations and showcase potential gaps in the literature, by compiling the results of different systematic reviews, meta-analyses and network meta-analyses (McKenzie and Brennan, 2017).

Within this framework, we performed an overview of systematic reviews aiming to summarize the current evidence regarding the efficacy and safety of PDE5 inhibitors for the management of ED.

Methods and Analysis

Data Sources and Searches

All findings in our study are reported in accordance with the PRIO-harms guidelines (Bougioukas et al., 2018; Bougioukas et al., 2019). We published our predefined protocol after registering the aims and methods of this overview of systematic reviews at PROSPERO (CRD42020216754) (Pyrgidis et al., 2021).

Two authors (NP, MT) systematically searched PubMed, Web of Science, The Cochrane Library and Scopus databases from inception to June 12, 2021. They also perused the reference lists of all identified studies, as well as potential sources of grey literature, including conference abstracts published in relevant journals and websites for healthcare evidence such as epistemonikos.org. The detailed search strategy is depicted in Supplementary Data S1.

Selection Criteria

We included systematic reviews with or without meta-analysis in adults with ED performing heterosexual activity that: i) compared the efficacy and safety of any dose of PDE5 inhibitors with another PDE5 inhibitor, with placebo or with other effective treatments; ii) provided outcomes of interest deriving from randomized controlled trials (RCTs); iii) explored the use of any approved PDE5 inhibitor by the EMA and FDA (avanafil, sildenafil, tadalafl, and vardenafil) alone or in combination with other treatment modalities both in the general male population, as well as in specific patient groups and; iv) were conducted based on the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA statement. On the other hand, we excluded: i) systematic reviews or meta-analyses assessing the efficacy and safety of PDE5 inhibitors for indications not relevant to erectile function and; ii) narrative reviews, editorials or letters to the editor.

When we identified both systematic reviews and meta-analyses addressing similar outcomes, the meta-analyses were only included, given that they included more primary studies. Similarly, when we identified systematic reviews or meta-analyses and network meta-analyses addressing similar outcomes, the network meta-analyses were only included, given that they included more primary studies. When we identified studies with the same design (systematic reviews or meta-analyses or network meta-analyses) addressing similar outcomes, ideally the most recent study or, otherwise, the most methodologically rigorous study, based on quality assessment, was included (Cooper and Koenka, 2012). Therefore, for each outcome, we
included only one study, preferably a network meta-analysis followed by a meta-analysis and a systematic review.

**Data Extraction and Quality Assessment**

Two authors (NP, MT) independently performed a three-step parallel review of title, abstract and full text of all retrieved records based on our predetermined selection criteria. All records excluded at the level of full text evaluation were saved and presented in Supplementary Data S2. Any discrepancies throughout the screening process were resolved by consensus. Data extraction was undertaken independently in a Microsoft Excel spreadsheet. The two authors tabulated information regarding study characteristics, intervention details and outcomes. They also performed a pilot test before data extraction to ensure the coherence of the procedure (Higgins et al., 2019). In studies evaluating the effect of PDE5 inhibitors on erectile function with multiple questionnaires, data regarding the International Index of Erectile Function (IIEF)–Erectile Function Domain or IIEF-5 were only extracted.

We employed the AMSTAR 2 tool to assess the quality of all included systematic reviews, meta-analyses or network meta-analyses (Shea et al., 2017). The extent of overlapping among included studies was estimated based on the corrected covered area (CCA) and was presented with novel graphical approaches (Pieper et al., 2014; Bougioukas et al., 2021). The strength of evidence for each meta-analytic effect was determined based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (Guyatt et al., 2008). In particular, we evaluated the strength of evidence of each meta-analytic effect based on the corresponding results from the systematic review.

**Outcomes and Data Analysis**

The primary outcome of our overview was the mean change in the erectile function after PDE5 inhibitor intake in the general population measured with the IIEF-5 or the IIEF–Erectile Function Domain. Secondary outcomes included: i) mean change in the erectile function after PDE5 inhibitor intake in specific patient groups based on data availability measured with the IIEF and; ii) severe adverse events and dropouts after PDE5 inhibitor intake both in the general population, as well as in specific patient groups based on data availability.

We performed a descriptive analysis of all included studies. For studies performing meta-analyses or network meta-analyses, we constructed forest plots with the corresponding confidence interval (CI) for all relevant meta-analytic effects. In particular, continuous effect estimates were presented in the form of standardized mean difference (SMD) or weighted mean difference (WMD), while categorical effect estimates were presented in the form of odds ratio (OR). When we identified studies that performed meta-analyses with a fixed effects model, we reanalyzed all outcomes using the DerSimonian and Laird random effects model.

For each outcome, heterogeneity was evaluated with the $I^2$ and publication bias was estimated with the Egger’s statistical test. Due to the plethora of primary studies included in each meta-analysis, all relevant measures were presented as they were reported in each study without reviewing the corresponding primary studies (Aromataris et al., 2015). All analyses were undertaken using Microsoft Excel (Version 16.42) and R statistical software (version 3.6.3).

**RESULTS**

**Study Selection and Characteristics**

Our literature search yielded 686 potentially eligible unique systematic reviews. Ultimately, we included 23 systematic reviews with 563 primary studies and 154,796 participants (Shabsigh et al., 2007; Vecchio et al., 2010; Xiao et al., 2012; Taylor et al., 2013; Yuan et al., 2013; Schmidt et al., 2014; Chen et al., 2015; García-Perdomo et al., 2017; Tan et al., 2017; Tian et al., 2017; Allen et al., 2019; D’Andrea et al., 2019; Lai et al., 2019; Li et al., 2019; Liao et al., 2019; Liu et al., 2019; Munk et al., 2019; Zhou et al., 2019; Adamou et al., 2020; Madeira et al., 2020; Wang et al., 2020; Zhu et al., 2020; Mykoniatis et al., 2021). Of them, 20 were meta-analyses or network meta-analyses that included a total of 258 relevant meta-analytic effects (Shabsigh et al., 2007; Vecchio et al., 2010; Xiao et al., 2012; Taylor et al., 2013; Yuan et al., 2013; Schmidt et al., 2014; Chen et al., 2015; García-Perdomo et al., 2017; Tan et al., 2017; Tian et al., 2017; D’Andrea et al., 2019; Lai et al., 2019; Li et al., 2019; Liao et al., 2019; Liu et al., 2019; Zhou et al., 2019; Adamou et al., 2020; Madeira et al., 2020; Wang et al., 2020; Zhu et al., 2020; Mykoniatis et al., 2021). The step-by-step screening procedure is illustrated in Supplementary Data S2 and Supplementary Data S3.

The baseline characteristics of the included systematic reviews are presented in Table 1. Overall, a total of 12 studies were funded. Accordingly, the mean overall AMSTAR 2 score of 11 ± 2.9 indicated that the methodological quality of most of the included systematic reviews was generally of sufficient standard (Supplementary Data S4). Across the included studies, the Egger’s test was only reported for 4 meta-analytic effects and no publication bias was detected. The non-reporting of publication bias was predominantly attributed to the low number of studies (<10) included for each meta-analytic effect. Overall, heterogeneity was available for 74 meta-analytic effects, of which 33 displayed substantial heterogeneity ($I^2 > 50\%$). The mean heterogeneity was 36\% (range: 0–99\%). Furthermore, the overall CCA was 3\%, while the CCA for the primary outcome was 37.4\%. The corresponding graphical analyses can be seen in Figure 1 and in Supplementary Data S5.

**Efficacy of Phosphodiesterase Type 5 Inhibitors**

Three network meta-analyses have addressed the efficacy of all approved PDE5 inhibitors on ED compared to each other or to placebo in the general population. Yuan et al. (2013) explored, for the first time, the efficacy of all approved PDE5 inhibitors without accounting for the different dosages and formulations of each PDE5 inhibitors. Subsequently, Chen et al. (2015) performed a trade-off network meta-analysis to account for these differences and to combine outcomes deriving from the four most important
ED questionnaires, namely the IIEF-5 or IIEF–Erectile Function Domain, the Sexual Encounter Profile (SEP) question 2 (SEP-2) and 3 (SEP-3), as well as the Global Assessment Questionnaire question 1 (GAQ-1). However, since most included studies did not provide data on one or more of the four questionnaires, the authors applied multiple imputations to perform these analyses (Chen et al., 2015). In an attempt to harmonize clinical outcomes and heterogeneity, Madeira et al. (2020) recently performed a network meta-analysis including studies that assessed ED only with the IIEF-5 or IIEF–Erectile Function Domain.

Combining the outcomes of all available dosages, Yuan et al. (2013) suggested that tadalafil may be considered the most effective compound in the general population, followed by vardenafil. Hence, based on the network meta-analysis by Chen et al. (2015) sildenafil 50 mg (SMD: 0.47, 95% CI: 0.34–0.59) followed by sildenafil 100 mg (SMD: 0.46, 95% CI: 0.35–0.56) were considered the treatments of choice when compared to placebo. In the most recent network meta-analysis by Madeira et al. (2020) sildenafil 25 mg (WMD: 13.08, 95% CI: 10.1–16.06) seemed to be statistically superior to all interventions in improving the IIEF compared to placebo, but studies with low-dose sildenafil are lacking. Still, comparing among different PDE5 inhibitors, sildenafil 50 mg or sildenafil 100 mg seem to be the most effective compounds in the general population. The latter derived, however, predominantly from indirect comparisons among different PDE5 inhibitors (Yuan et al., 2013; Madeira et al., 2020). Of interest, low-dose daily tadalafil may be more effective for the management of ED than high-dose on-demand tadalafil (WMD: 1.24, 95% CI: 0.03–2.44) (Zhou et al., 2019).

Overall, in the available studies, the strength of evidence for most pairwise comparisons between different dosages and formulations of PDE5 inhibitors was considered low or very low due to the lack of high-quality RCTs comparing different types of PDE5 inhibitors. All relevant meta-analytic effects are summarized in Figure 2 and Supplementary Data S6.

In specific patient populations, the efficacy of PDE5 inhibitors is also well documented. In particular, the available evidence suggests that, in patients with diabetes, all PDE5 inhibitors are superior to placebo (Liao et al., 2019). Comparing among different formulations of PDE5 inhibitors, vardenafil and sildenafil on-demand display the highest efficacy (Liao et al., 2019). In patients with prostatectomy-induced ED, PDE5 inhibitors at any dosage and formulation are superior to placebo and are also recommended as part of penile rehabilitation strategies (Tian et al., 2017). Similarly, their superiority is observed in individuals with hypertension, chronic kidney disease, renal transplantation, spinal cord injury, multiple sclerosis or other neurogenic disorders, obstructive sleep apnea and antidepressant- or antipsychotic-related ED (Shabsigh et al., 2007; Vecchio et al., 2010; Xiao et al., 2012; Taylor et al., 2013; García-Perdomo et al., 2017; Allen et al., 2019; Li et al., 2019; Liu et al., 2019). Of note, in patients with psychogenic ED, the current evidence indicates that no
significant differences are demonstrated between PDE5 inhibitor monotherapy and psychological interventions (WMD: $-0.28$, 95% CI: $-1.19$–$0.64$) (Schmidt et al., 2014). Nevertheless, the level of evidence for most outcomes based on the GRADE approach was deemed low or very low. The corresponding meta-analytic effects are presented in Figure 3.

Safety of Phosphodiesterase Type 5 Inhibitors

Compared to placebo, all dosages and formulations of PDE5 inhibitors present more treatment-related adverse events based on the three network meta-analyses by Yuan et al. (2013), Chen et al. (2015), and Madeira et al. (2020). Hence, the ORs for developing severe adverse events, compared to placebo, do not reach statistical significance for all dosages of PDE5 inhibitors. The within group safety analysis demonstrated that there are no major differences among different PDE5 inhibitors in the general population. Still, sildenafil 100 mg seems to be associated with more treatment-related adverse events and discontinuations due to adverse events (Madeira et al., 2020). Of note, PDE5 inhibitors do not seem to significantly improve endothelial function compared to placebo both in the general population and in patients with diabetes (D’Andrea et al., 2019). Similarly, PDE5 inhibitors do not affect semen parameters (Tan et al., 2017). The relevant comparisons are available in Supplementary Data S7.

Role of Phosphodiesterase Type 5 Inhibitors as Part of Combination Treatment

The addition of testosterone in patients with ED and hypogonadism treated with PDE5 inhibitors seems to further improve erectile function (Zhu et al., 2020). In particular, among patients receiving transdermal or oral testosterone due to hypogonadism, sildenafil on-demand at a dose of 50 or 100 mg, as well as 5 mg daily tadalaflit display a safe and effective profile. Still, no clear recommendations about the optimal type and dose of treatment can be made. On the other hand, although PDE5 inhibitors improve erectile function in patients with lower urinary tract symptoms (WMD: $-4.77$, 95% CI: $-6.40$–$-3.14$), the addition of a-blockers does not further ameliorate symptoms (WMD: $-0.8$, 95% CI: $-1.65$–$0.06$) (Adamou et al., 2020). In the Chinese general population, the combination of Chinese herbal medicine and tadalaflit compared to tadalaflit monotherapy may provide beneficial outcomes on ED (WMD: $-2.67$, 95% CI: $-3.15$ to $-2.19$) (Wang et al., 2020). In patients with psychogenic ED, the addition of acupuncture to tadalaflit or sildenafil seems to further improve erectile function (Lai et al., 2019), while the addition of PDE5 inhibitors to psychological interventions does not improve symptoms compared to psychological interventions alone (Schmidt et al., 2014). Interestingly, adding to a PDE5 inhibitor: a second PDE5 inhibitor, low-intensity shockwave therapy, a vacuum erectile device or antioxidants is effective in patients with ED, while folic acid, metformin and angiotensin-converting enzyme inhibitors may be effective in some patients with ED but the evidence is still scarce (Munk et al., 2019). The effect of all available combination therapies with PDE5 inhibitors is presented in Figure 4.

DISCUSSION

Our overview of systematic reviews summarizes the available evidence about PDE5 inhibitors and demonstrates their safety
FIGURE 3 | Efficacy of different PDE5 inhibitors in various patient groups. CI: confidence interval; ED: erectile dysfunction; GRADE: grading of recommendations assessment, development and evaluation; NA: not available; PDE5: phosphodiesterase type 5; RCT: randomized controlled trial; SMD: standardized mean difference; WMD: weighted mean difference.

FIGURE 4 | Efficacy of combination therapy with PDE5 inhibitors in various patient groups compared to monotherapy. CI: confidence interval; ED: erectile dysfunction; GRADE: grading of recommendations assessment, development and evaluation; LUTS: lower urinary tract symptoms; NA: not available; PDE5: phosphodiesterase type 5; RCT: randomized controlled trial; SMD: standardized mean difference; WMD: weighted mean difference.
**TABLE 1** Baseline characteristics of the included systematic reviews. AMSTAR: a measurement tool to assess systematic reviews; CBM: China biological/medicine; CPAP: continuous positive airway pressure; ED: erectile dysfunction; MA: meta-analysis; NA: not available; NMA: network meta-analysis; NOS: Newcastle-Ottawa scale; PDE5: phosphodiesterase type 5; RCT: randomized controlled trial; ROB: risk of bias; SR: systematic review.

| Study                  | Design | RCTs (n) | Outcomes                                                                 | Participants (n) | Databases searched                                                                 | Quality assessment of primary studies | Funded | AMSTAR 2 total score |
|------------------------|--------|----------|---------------------------------------------------------------------------|-----------------|-----------------------------------------------------------------------------------|---------------------------------------|--------|----------------------|
| Allen et al. (2019)    | SR     | 6        | PDE5 inhibitors vs. placebo in patients with antipsychotic-related sexual dysfunction | 175             | PubMed, embase, PsycINFO                                                          | ROB No                               |        | 7                    |
| Chen et al. (2015)     | NMA    | 102      | PDE5 inhibitors vs. PDE5 inhibitors or placebo                            | 47,628          | PubMed                                                                             | NA Yes                                |        | 5                    |
| D’Andrea et al. (2019) | MA     | 13       | PDE5 inhibitors vs. placebo for endothelial dysfunction                   | 932             | PubMed, Scopus, CINAHL, Science Direct, The Cochrane Library                      | ROB No                               |        | 14                   |
| Adamou et al. (2020)   | MA     | 5        | PDE5 inhibitors plus a-blocker vs. monotherapy                           | 503             | PubMed, Scopus, The Cochrane Library, Web of Science                             | ROB No                               |        | 12.5                 |
| Lai et al. (2019)      | MA     | 5        | PDE5 inhibitors plus acupuncture vs. PDE5 inhibitors                      | 1751            | PubMed, The Cochrane Library, Sinome database, China National Knowledge Infrastructure, Wanfang database, China Science Technology Journal database | ROB Yes                               |        | 9.5                  |
| Li et al. (2019)       | MA     | 7        | PDE5 inhibitors vs. CPAP in patients with obstructive sleep apnea         | 322             | PubMed, embase, Web of Science                                                   | ROB Yes                               |        | 14                   |
| Liao et al. (2019)     | NMA    | 15       | PDE5 inhibitors vs. other PDE5 inhibitors or placebo in patients with diabetes | 5,274           | PubMed, The Cochrane Library, embase, Scopus                                      | ROB Yes                               |        | 12.5                 |
| Liu et al. (2019)      | MA     | 7        | Sildenafil vs. placebo after renal transplantation                         | 332             | PubMed, Springer, embase, OVID, The Cochrane Library, PubMed, Scopus, Web of Science, ClinicalTrials.gov | ROB No                               |        | 13                   |
| Madeira et al. (2020)  | NMA    | 179      | PDE5 inhibitors vs. PDE5 inhibitors or placebo                            | 50,620          | PubMed, The Cochrane Library, PubMed, Scopus, Web of Science, ClinicalTrials.gov | ROB Yes                               |        | 14                   |
| Munk et al. (2019)     | SR     | 7        | PDE5 inhibitors combination therapy vs. PDE5 inhibitors monotherapy       | 718             | PubMed, embase, Clinical Trials                                                  | ROB No                               |        | 8                    |
| Mykoniatis et al. (2021)| MA    | 32       | PDE5 inhibitors plus another agent vs. PDE5 inhibitors monotherapy        | 2,788           | PubMed, The Cochrane Library, embase                                              | ROB Yes                               |        | 15                   |
| Garcia-Perdomo et al. (2017)| MA | 6 | PDE5 inhibitors vs. placebo in patients with spinal cord injury | 963             | PubMed, The Cochrane Library, embase                                              | ROB No                               |        | 11                   |
| Schmidt et al. (2014)  | MA     | 8        | PDE5 inhibitors plus psychological interventions vs. PDE5 inhibitors monotherapy | 562             | PubMed, embase, PsycINFO, The Cochrane Library, PSYNDEX                            | ROB No                               |        | 12                   |
| Shabsigh et al. (2007) | MA     | 4        | Vardenafil in hypertensive patients                                      | 2,427           | NA                                                                                | NA Yes                                |        | 6.5                   |
| Tan et al. (2017)      | MA     | 11       | Semen parameters before and after PDE5 inhibitors intake                  | 1,317           | PubMed, embase, The Cochrane Library, Web of Science, ClinicalTrials.gov         | ROB Yes                               |        | 8.5                  |
| Taylor et al. (2013)   | MA     | 5        | PDE5 inhibitors vs. placebo or other treatments in patients with antidepressant-induced sexual dysfunction | 1886            | PubMed, The Cochrane Library, Web of Science, ClinicalTrials.gov, ITRP             | ROB Yes                               |        | 14.5                 |
| Tian et al. (2017)     | MA     | 8        | PDE5 inhibitors vs. placebo after nerve-sparing radical prostatectomy     | 1806            | PubMed and embase                                                                  | ROB No                               |        | 10                   |
| Vecchio et al. (2010)  | MA     | 4        | PDE5 inhibitors vs. placebo in patients with chronic kidney disease      | 328             | PubMed, The Cochrane Library, embase, Cochrane Renal Group’s Specialized Register | ROB No                               |        | 7.5                   |
| Wang et al. (2020)     | MA     | 11       | Tadalafil plus chinese herbal medicine vs. tadalafil monotherapy         | 903             | PubMed, The Cochrane Library, embase, CNKI, Wanfang, Weip database, CBM            | ROB No                               |        | 12.5                 |
| Xiao et al. (2012)     | MA     | 2        |                                                                                | 420             | PUBMED The Cochrane Library, embase, CBM                                          | ROB No                               |        | 11                   |

(Continued on following page)
and efficacy both as monotherapy and as part of combination therapy. In patients prioritizing high efficacy with tolerability, sildenafil at low doses (25 or 50 mg) followed by tadalafil may be considered the first-line ED treatment. Still, this observation derives predominantly from indirect comparisons with placebo, since RCTs directly comparing the available PDE5 inhibitors are scarce. PDE5 inhibitors are also effective and safe in almost all patient groups with organic ED, including difficult-to-treat subgroups, such as individuals with diabetes, hypertension, chronic kidney disease, prostatectomy-induced ED and neurological disorders. Still, PDE5 inhibitors do not seem to improve endothelial function.

The development and launch of PDE5 inhibitors more than 2 decades ago have brought upon a revolution for the management of ED (Goldstein et al., 1998). Their safety profile, rapid efficacy, convenient oral administration, availability on an over-the-counter basis and relatively low cost has made them one of the most commonly administered medications (Martin et al., 2013). It should be stressed that low-dose PDE5 inhibitors such as sildenafil 25 mg or tadalafil 5 mg seem to combine high efficacy with lower treatment-related adverse events compared to the same compounds at higher dose. Thus, further RCTs comparing the safety and efficacy profile of PDE5 inhibitors at low dose versus PDE5 inhibitors at high dose are necessary.

PDE5 inhibitors induce corporeal smooth muscle relaxation that increases arterial blood flow, which is followed by compression of the sub-tunical venous plexus and, in turn, leads to erection of the penis (Lue, 2000). Animal models have demonstrated that chronic daily PDE5 inhibitor intake may improve cavernosal endothelial function (Behr-Roussel et al., 2005; Kovanecz et al., 2008). However, these findings have not been replicated in humans (Pattanaik et al., 2019). Based on the previous notion, the included meta-analysis about the effect of PDE5 inhibitors on endothelial function demonstrated that PDE5 inhibitors do not seem to significantly ameliorate endothelial dysfunction and highlighted the need for high-quality primary studies (D’Andrea et al., 2019). In this context, daily tadalafil may be equally effective as on-demand tadalafil (Porst et al., 2014) and the combination of daily tadalafil with on-demand sildenafil may further improve erectile function, especially in patients with severe ED (Cui et al., 2015).

Given that combination treatment with PDE5 inhibitors and testosterone is safe and effective compared to monotherapy of PDE5 inhibitors (Spitzer et al., 2012), it may be advised to initially prefer combination therapy with testosterone and PDE5 inhibitors in patients with hypogonadism (Tsertsuvadze et al., 2009). Still, studies exploring the optimal dose and form of administration of both PDE5 inhibitors and testosterone are mandatory. On the contrary, the addition of a-blockers to PDE5 inhibitors does not seem to improve symptoms compared to monotherapy of PDE5 inhibitors in patients with lower urinary tract symptoms and ED. Nevertheless, due to the paucity of available evidence, future relevant studies are expected with great interest.

In non-responders to PDE5 inhibitors or in patients with difficult-to-treat ED, the addition of low-intensity shockwave therapy, a vacuum erectile device or antioxidants may further improve erectile function without increasing the number of adverse events (Morano et al., 2007; Engel, 2011; Baccaglini et al., 2020). However, it should be noted that no exact definitions of non-responders to PDE5 inhibitors and of patients with difficult-to-treat ED exist. Non-responders to PDE5 inhibitors are considered all patients on regular PDE5 inhibitors that abandon treatment due to inefficacy. In such cases, the partner and/or the circumstances surrounding the sexual encounter should be also taken into consideration before classifying somebody as non-responder (Hatzichristou et al., 2005). In particular, one disadvantage of sildenafil is that it acts approximately 1 h after intake and demands avoidance of food or alcohol, which alters the sexual encounter into a timed activity (McCullough et al., 2002). Accordingly, difficult-to-treat ED is defined as the ED that is unresponsive, refractory or relapsing to PDE5 inhibitors. Of note, in this setting, the exclusion of psychogenic ED is necessary, given that PDE5 inhibitors are ineffective (Burnett et al., 2018). In cases of documented difficult-to-treat ED, the increase of the initial PDE5 inhibitor dose may provide some short-term efficacy, but soon clinicians should opt for combination therapies (Salonia et al., 2021). Nevertheless, it should be highlighted that studies evaluating the optimal combination strategies are scarce.

TABLE 1 (Continued) Baseline characteristics of the included systematic reviews. AMSTAR: a measurement tool to assess systematic reviews; CBM: China biological/medicine. CPAP: continuous positive airway pressure; ED: erectile dysfunction; MA: meta-analysis; NA: not available; NMA: network meta-analysis; NOS: Newcastle Ottawa scale; PDE5: phosphodiesterase type 5; RCT: randomized controlled trial; ROB: risk of bias; SR: systematic review.

| Study              | Design | RCTs (n) | Outcomes                                      | Participants (n) | Databases searched                  | Quality assessment of primary studies | Funded | AMSTAR 2 total score |
|--------------------|--------|----------|-----------------------------------------------|------------------|-------------------------------------|--------------------------------------|--------|---------------------|
| Yuan et al. (2013) | NMA    | 114      | Sildenafil vs. placebo or no treatment in patients with multiple sclerosis | 31,196           | PubMed, The Cochrane Library, embase | ROB Yes                               |         | 13                  |
| Zhou et al. (2019) | MA     | 4        | Tadalafil daily vs. tadalafi on demand         | 1,035            | PubMed, The Cochrane Library, embase | ROB Yes                               |         | 13                  |
| Zhu et al. (2020)  | MA     | 8        | PDE5 inhibitors plus testosterone vs. PDE5 inhibitors monotherapy in men with hypogonadism | 913              | PubMed, The Cochrane Library, embase | ROB Yes                               |         | 10                  |
Patients treated with PDE5 inhibitors display high discontinuation rates due to adverse events or inefficacy and, thus, research on novel ED treatment is imperative (Burnett and Hellstrom, 2012). Promising single or combination treatment modalities that may comprise growth factor therapy, stem cell therapy, or even gene therapy and tissue engineering may make their way through the clinical pipeline (Poulios et al., 2021; Raheem et al., 2021). Consequently, studies comparing the efficacy and safety of such treatment strategies in the form of monotherapy or combination therapy with PDE5 inhibitors are mandatory.

Limitations
The findings of the present study should be interpreted with respect to some limitations. Due to the plethora of primary studies and due to the complexity of some meta-analytic effects, we did not review the primary studies included in each systematic review and did not consider further primary studies published after these systematic reviews. Therefore, for all measures and outcomes, we relied on the information presented in each included systematic review. Even though we included only systematic reviews and meta-analyses of RCTs to provide high level of evidence, the impact of observational, real-world data on the safety and efficacy of PDE5 inhibitors remains uncaptured. Importantly, some systematic reviews and meta-analyses were of low methodological quality, while others displayed high quality and significantly contributed to our results. Based on the previous notion, it should be stressed that, for each outcome, the most methodologically rigorous study based on study design, protocol existence, duplication of data extraction, application of recommended tools and performance of sophisticated statistical analyses was only included. Still, despite our objective criteria, some important studies might have been excluded. Moreover, it was beyond the scope of this review to explore the role of PDE5 inhibitors in disorders not relevant to ED such as premature ejaculation, priapism or pulmonary hypertension. Finally, it should be stressed that all overviews of systematic reviews suffer from the limitation that they summarize a broad topic and much of the information provided in individual studies or systematic reviews cannot be reported in detail.

CONCLUSION
This overview of systematic reviews suggests that, although the efficacy and safety of PDE5 inhibitors, compared to placebo, is well-documented both in the general population and in most patient groups with difficult-to-treat ED, the vast amount of existing evidence comparing different PDE5 inhibitors is low. Therefore, high-quality, head-to-head, multicenter RCTs comparing different PDE5 inhibitors are necessary to determine their ideal dosage and formulation based on their safety and efficacy profile. Nevertheless, according to our findings, sildenafil or tadalafil at low dose seem to display high efficacy and safety. Moreover, combination therapy with PDE5 inhibitors plus other effective agents has emerged as a promising treatment modality in patients with refractory, complex or difficult-to-treat ED. Still, further studies producing evidence on the optimal treatment formulation are warranted to establish combination therapy as first-line treatment for ED.

DATA AVAILABILITY STATEMENT
The original contributions presented in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
All authors participated in the drafting, writing, and editing of the manuscript. NP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

FUNDING
This research has been co-financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH—CREATE—INNOVATE (project code: T1EDK-00540). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.735708/full#supplementary-material

REFERENCES
Adamou, C., Kallidonis, P., Kotsiris, D., Ntasiotis, P., Verze, P., Athanasopoulos, A., et al. (2020). Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur. Urol. Focus 6, 537–558. doi:10.1016/j.euf.2019.05.007
Allen, K., Baban, A., Munjiza, J., and Pappa, S. (2019). Management of Antipsychotic-Related Sexual Dysfunction: Systematic Review. J. Sex. Med. 16, 1978–1987. doi:10.1016/j.jsxm.2019.08.022
Allen, M. S., and Walter, E. E. (2019). Erectile Dysfunction: An Umbrella Review of Meta-Analyses of Risk-Factors, Treatment, and Prevalence Outcomes. J. Sex. Med. 16, 531–541. doi:10.1016/j.jsxm.2019.01.314
Aromataris, E., Fernandez, R., Godfrey, C. M., Holly, C., Khalil, H., and Tungumperkom, P. (2015). Summarizing Systematic Reviews: Methodological Development, Conduct and Reporting of an Umbrella Review Approach. Int. J. Evid. Based Healthc. 13, 132–140. doi:10.1097/XEB.0000000000000055
Baccañlini, W., Pazeto, C. L., Corrêa Barros, E. A., Timóteo, F., Monteiro, L., Saad Rached, R. Y., et al. (2020). The Role of the Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after Radical Prostatectomy: A
Hatzichristou, D., Moy sis, K., Apostolidis, A., Bekos, A., Tzortzis, V., Hatzimouratidis, K., et al. (2005). Sildenafil Failures May Be Due to Inadequate Patient Instructions and Follow-Up: A Study on 100 Non-responders. Eur. Urol. 47, 518–523. discussion 522–523. doi:10.1016/j.eururo.2004.12.005

Hunt, H., Pollock, A., Campbell, P., Estcourt, L., and Brunton, G. (2018). An Introduction to Overviews of Reviews: Planning a Relevant Research Question and Objective for an Overview. Syst. Rev. 7, 39. doi:10.1186/s13646-018-0699-5

J. P. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, and M. J. W. V. Page (2019). in Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition (Chichester (UK): John Wiley & Sons).

Kovanezz, L., Rabbahla, A., Ferrini, M. G., Vernet, D., Sanchez, S., Rafter, J., et al. (2008). Chronic Daily Tadalafil Prevents the Corporal Fibrosis and Veno-Occlusive Dysfunction that Occurs after Cavernosal Nerve Resection. BJU Int. 100, 201–210. doi:10.1111/j.1445-4110.2007.07223.x

Lai, B. Y., Cao, H. J., Yang, G. Y., Jia, L. Y., Grant, S., Fei, Y. T., et al. (2019). Acupuncture for Treatment of Erectile Dysfunction: A Systematic Review and Meta-Analysis. World J. Mens Health 37, 322–338. doi:10.5534/wjm.2018090

Li, Z., Fang, Z., Xing, N., Zhu, S., and Fan, Y. (2019). The Effect of CPAP and PDE5i on Erectile Function in Men with Obstructive Sleep Apnea and Erectile Dysfunction: A Systematic Review and Meta-Analysis. Sleep Med. Rev. 48, 102127. doi:10.1016/j.smr.2019.102127

Liao, X., Qu, S., Bao, Y., Wang, W., Yang, L., and Wei, Q. (2019). Comparative Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction in Diabetic Men: a Bayesian Network Meta-Analysis of Randomized Controlled Trials. World J. Urol. 37, 1061–1074. doi:10.1007/s00345-018-2583-1

Liu, L. Y., Sun, T., Liu, Y., Sun, Y. Y., and Ma, F. Z. (2019). The Clinical Effects of Sildenafil for Erection in Patients after Kidney Transplantation: A Meta-Analysis. Nephron 141, 1–9. doi:10.1159/000492237

Lue, T. F. (2000). Erectile Dysfunction. N. Engl. J. Med. 342, 1802–1813. doi:10.1056/NEJM200006133422407

Madeira, C. R., Tonin, F. S., Fachi, M. M., Borba, H. H., Ferreira, V. L., Leonart, L. P., et al. (2020). Efficacy and Safety of Oral Phosphodiesterase 5 Inhibitors for Erectile Dysfunction: a Network Meta-Analysis and Multicriteria Decision Analysis. J. Urol. 39, 953–962. doi:10.1001/s00345-020-03239-9

Martin, A. L., Huelin, R., Wilson, D., Foster, T. S., and Mold, J. F. (2013). A Systematic Review Assessing the Economic Impact of Sildenafil Citrate (Viagra) in the Treatment of Erectile Dysfunction. J. Sex. Med. 10, 1389–1400. doi:10.1111/jsm.12068

McCullough, A. R., Barada, J. H., Fawzy, A., Guay, A. T., and Hatzichristou, D. (2002). Achieving Treatment Optimization with Sildenafil Citrate (Viagra) in Patients with Erectile Dysfunction. Urology 60, 28–38. doi:10.1016/s0090-4295(02)01688-6

McKenzie, J. E., and Brennan, S. E. (2017). Overview of Systematic Reviews: Great Promise, Greater challenge. Syst. Rev. 6, 185. doi:10.1186/s13643-017-0582-8

Morano, S., Mandosi, E., Fallario, M., Gatti, A., Tiberi, C., Sensi, M., et al. (2007). Antioxidant Treatment Associated with Sildenafil Reduces Monocyte Activation and Markers of Endothelial Damage in Patients with Diabetic Erectile Dysfunction: a Double-Blind, Placebo-Controlled Study. Eur. Urol. 52, 1768–1774. doi:10.1016/j.eururo.2007.04.042

Munk, N. E., Knudsen, J. S., Comerma-Steffensen, S., and Simonsen, U. (2019). Systematic Review of Oral Combination Therapy for Erectile Dysfunction when Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. Sex. Med. Rev. 7, 430–441. doi:10.1016/j.sxmr.2018.11.007

Mykoniotis, I., Pyrgis, N., Sokolakis, I., Ouralidis, A., Sountoulides, P., Haichid, A. B., et al. (2021). Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-Analysis. JAMA Netw. Open 4, e203637. doi:10.1001/jamanetworkopen.2020.36337

Pattanaik, S., Kaundal, P., Mavuduru, R. S., Singh, S. K., and Mandal, A. K. (2019). Endothelial Dysfunction in Patients with Erectile Dysfunction: a Double-Blind, Randomized-Control Trial Using Tadalafil. Sex. Med. 7, 41–47. doi:10.1016/j.jsexmed.2018.11.008

Pieper, D., Antoine, S. L., Mathes, T., Neugebauer, E. A., and Eikermann, M. (2014). Systematic Review Finds Overlapping Reviews were Not Mentioned in Every Other Overview. J. Clin. Epidemiol. 67, 368–375. doi:10.1016/j.jclinepi.2013.11.007

Engel, J. D. (2011). Effect on Sexual Function of a Vacuum Erection Device post- prostatectomy. Can. J. Urol. 18, 5721–5725.

Garcia-Perdomo, H. A., Echeverria-Garcia, F., and Tobias, A. (2017). Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis. Eur. Urol. Int. 98, 198–204. doi:10.1159/000448290

Goldstein, L., Burnett, A. L., Rosen, R. C., Park, P. W., and Stecher, V. J. (2019). The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. Sex. Med. Rev. 7, 115–128. doi:10.1016/j.sxmr.2018.06.005

Goldstein, L., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., and Wicker, P. A. (1998). Oral Sildenafil in the Treatment of Erectile Dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338, 1397–1404. doi:10.1056/NEJM19980514378201

Greenberg, D. R., Richardson, J. M., Tijerina, J. D., Mass, B. B., and Eisenberg, M. L. (2019). The Quality of Systematic Reviews and Meta-Analyses in Erectile Dysfunction Treatment and Management Published in the Sexual Medicine Literature. J. Sex. Med. 16, 394–401. doi:10.1016/j.jsexmed.2019.01.009

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. (2008). GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations. BMJ 336, 924–926. doi:10.1136/bmj.39489.470347.AD
Porst, H., Gacci, M., Böttner, H., Henneges, C., and Boess, F. (2014). Tadalafil once Daily in Men with Erectile Dysfunction: an Integrated Analysis of Data Obtained from 1913 Patients from Six Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. *Eur. Urol.* 65, 455–464. doi:10.1016/j.eururo.2013.09.037

Poullos, E., Mykoniotis, I., Kapoteliziotis, P. Kotsiris, D., and Kalvyanakis, D. Hatzichristou, D. (2021). Platelet-Rich Plasma (PRP) Improves Erectile Function: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *J. Sex. Med.* 18, 926–935. doi:10.1016/j.jsxm.2021.03.008

Pyrgidis, N., Mykoniotis, I., Haidich, A.-B., Tirta, M., Talimtzis, P., Kalvyanakis, D., et al. (2021). Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: an Overview of Systematic Reviews and Meta-Analyses. *BMJ Open* 11 (8), e047396. doi:10.1136/bmjopen-2020-047396

Raheem, O. A., Natale, C., Dick, B., Reddy, A. G., Querques, M., et al. (2010). Treatment Options for Sexual Dysfunction in Patients with Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials. *Cjasn* 5, 985–995. doi:10.2215/CJN.09081209

Wang, Y. L., Geng, L. G., He, C. B., and Yuan, S. Y. (2020). Chinese Herbal Medicine Combined with Tadalafil for Erectile Dysfunction: A Systematic Review and Meta-Analysis. *Andrology* 8, 268–276. doi:10.1111/andr.12696

Xiao, Y., Wang, J., and Luo, H. (2012). Sildenafil Citrate for Erectile Dysfunction in Patients with Multiple Sclerosis. *Cochrane Database Syst. Rev. Published Online First*. doi:10.1002/14651858.CD009427.pub2

Yuan, J., Zhang, R., Yang, Z., Lee, J., Liu, Y., Tian, J., et al. (2013). Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-Analysis. *Eur. Urol.* 63, 902–912. doi:10.1016/j.eururo.2013.01.012

Zhou, Z., Chen, H., Wu, J., Wang, J., Zhang, X., Ma, J., et al. (2019). Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared with Tadalafil On-Demand in Treating Men with Erectile Dysfunction. *Sex. Med. J.* 7, 282–291. doi:10.1016/j.xsxm.2019.06.006

Zhu, J., Zhang, W., Ou, N., Song, Y., Kang, J., Liang, Z., et al. (2020). Do testosterone Supplements Enhance Response to Phosphodiesterase 5 Inhibitors in Men with Erectile Dysfunction and Hypogonadism: a Systematic Review and Meta-Analysis. *Transl Androl. Urol.* 9, 591–600. doi:10.2139/tau.2020.01.13

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Pyrgidis, Mykoniotis, Haidich, Tirta, Talimtzis, Kalvyanakis, Ouranidis and Hatzichristou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.